The National Eczema Association has published the first comprehensive report on atopic dermatitis that examines the condition at both the national and the state level, the organization announced via PR Newswire.

The report marks a milestone for the field. Until now, no single publication has consolidated data on atopic dermatitis across the entire United States with state-by-state granularity, according to the announcement. For dermatologists, public health officials and patient advocates, that gap has long complicated efforts to quantify the disease burden, compare regional patterns and direct resources where patients need them.

What does the report add?

The National Eczema Association positions the document as a foundational reference rather than a single-institution study. As the first comprehensive national and state-level report on atopic dermatitis, it aggregates the association's perspective on the disease into one resource intended for broad use by clinicians, policymakers and researchers.

The state-level structure is the notable design choice. National prevalence figures for atopic dermatitis exist in the literature, but a state-by-state breakdown allows stakeholders to see how the condition distributes geographically — information that matters for:

• State health departments allocating skin-disease resources
• Advocacy groups lobbying for coverage and access reforms
• Researchers designing regional epidemiologic studies
• Clinicians comparing local patient burdens against national benchmarks

Why state-level data matters for practice

Atopic dermatitis is one of the most common inflammatory skin conditions dermatologists manage, and treatment access varies widely by state — from biologic coverage criteria to specialist availability. A state-level report gives practicing dermatologists a way to anchor local advocacy and patient-education efforts in documented disease-burden figures rather than extrapolated national estimates.

The report also serves a policy function. First-of-kind national publications frequently become the citation of record in statehouse testimony, payer negotiations and grant applications. By consolidating atopic dermatitis data into a single authoritative document, the National Eczema Association gives stakeholders a common evidentiary baseline.

Who should read it

The association frames the report for a mixed audience. Dermatology practices can use it for patient communication and community outreach; public health agencies can use it for planning; and researchers can use it as a starting point for state-level analyses of atopic dermatitis prevalence, severity and care gaps.

For a condition that often receives less policy attention than psoriasis or skin cancer despite its high prevalence, a dedicated national report signals institutional commitment to elevating atopic dermatitis on the public health agenda.

Derm Field will monitor how clinicians and policymakers apply the report's findings as it circulates through state health systems in the coming months.